Page last updated: 2024-12-06

erdosteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Erdosteine is a mucolytic agent used to treat respiratory diseases. It acts by breaking down mucus in the lungs, making it easier to cough up. Erdosteine is synthesized from the amino acid L-cysteine. It is studied due to its potential to reduce the symptoms of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. '

Cross-References

ID SourceID
PubMed CID65632
CHEMBL ID1697744
CHEBI ID135014
SCHEMBL ID21721
MeSH IDM0139505

Synonyms (83)

Synonym
AC-5278
pv 144
(+-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic acid
rv 144
erdosteinum [latin]
acetic acid, ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)-
erdosteine [inn]
acide ((2-oxo-3-tetrahydrothienylcarbamoyl)-methylthio)acetique [french]
((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)acetic acid
dl-s-(2-(n-3-(2-oxotetrahydrotheinyl)acetamido))thioglycolic acid
dithiosteine
kw-9144
erdotin
rv-144
vectrine
erdosteine
edirel
mucotec (tn)
84611-23-4
erdosteine (inn)
D07383
CHEBI:135014
2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid
A840878
2-[2-oxo-2-[(2-oxotetrahydrothiophen-3-yl)amino]ethyl]sulfanylacetic acid;erdosteine
NCGC00185774-01
CHEMBL1697744
mucotec
105426-14-0
HMS3264C11
tox21_113176
dtxcid5028661
cas-84611-23-4
dtxsid8048735 ,
erdosteinum
unii-76j0853eka
erdosteine [inn:ban]
76j0853eka ,
acide ((2-oxo-3-tetrahydrothienylcarbamoyl)-methylthio)acetique
FT-0625684
FT-0630929
S1825
AKOS015888361
erdosteine [mi]
erdosteine [mart.]
erdosteine [who-dd]
(+/-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic acid
DB05057
CCG-213836
HY-B0289
MLS006010056
smr002529560
SCHEMBL21721
NCGC00185774-02
tox21_113176_1
erdostiene
KS-1352
AB01274804-01
E1026
n-(tetrahydro-2-oxo-3-thienyl)-3-thiapentanedioic acid monoamide
AB01274804_03
AB01274804_02
STL452949
({2-oxo-2-[(2-oxotetrahydrothiophen-3-yl)amino]ethyl}sulfanyl)acetic acid
acetic acid, [[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]-
SR-01000944253-1
sr-01000944253
2-((2-oxo-2-((2-oxotetrahydrothiophen-3-yl)amino)ethyl)thio)acetic acid
({2-oxo-2-[(2-oxotetrahydro-3-thienyl)amino]ethyl}sulfanyl)acetic acid
HMS3655I14
erdosteine, >=98% (hplc)
erdosteine;[[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]acetic acid; dithiosteine; erdostin; rv 144; secresolv
SW220302-1
Q3731252
erdosteine; [[2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]acetic acid
2-({[(2-oxothiolan-3-yl)carbamoyl]methyl}sulfanyl)acetic acid
mfcd00867664
erdosteine,(s)
2-(2-oxo-2-(2-oxotetrahydrothiophen-3-ylamino)ethylthio)acetic acid
NCGC00185774-09
T72990
secresolv
EN300-7361949

Research Excerpts

Overview

Erdosteine is a drug approved for the treatment of acute and chronic pulmonary diseases, originally developed as a mucolytic agent. It is a thiol compound having mucoactive, antioxidant, anti-inflammatory, and antitussive effects.

ExcerptReferenceRelevance
"Erdosteine is a mucolytic drug and has antioxidant activity."( Determination, Isolation, and Identification of Related Impurities in Erdosteine Bulk Drug.
Cheng, Q; Liu, H; Pei, K; Wang, J; Xiong, X; Zhong, Z; Zhou, Z, 2022
)
2.4
"Erdosteine is a drug approved for the treatment of acute and chronic pulmonary diseases, originally developed as a mucolytic agent. "( Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Calzetta, L; Cazzola, M; Matera, MG; Page, C; Rogliani, P, 2020
)
2.28
"Erdosteine is a mucolytic agent with antioxidant and anti-inflammatory effects. "( Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
Erdem, A; Fadillioglu, E; Gedikli, E; Karaismailoglu, S; Muftuoglu, S; Tuncer, M; Yersal, N, 2017
)
2.23
"Erdosteine is a thiol compound having mucoactive, antioxidant, anti-inflammatory, and antitussive effects and is reported to be safe for treatment of acute respiratory tract diseases in children."( Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu, G; Yavuz, SO, 2017
)
1.43
"Erdosteine is a thioderivative endowed with mucokinetic, mucolytic and free-radical-scavenging properties."( The protective effect of erdosteine on short-term global brain ischemia/reperfusion injury in rats.
Akyol, O; Bilgic, S; Cigli, A; Ilhan, A; Iraz, M; Ozerol, E, 2009
)
1.38
"Erdosteine is a thiol agent with a multifactorial mechanism of action, namely: mucolytic, antibacterial, antioxidant and anti-inflammatory activity. "( Erdosteine: its relevance in COPD treatment.
Moretti, M, 2009
)
3.24
"Erdosteine is an efficient adjuvant therapy that could be used in conjunction with first-line triple therapy in the treatment of H. "( Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut, E; Bölükbaş, C; Bölükbaş, FF; Dalay, AR; Güveli, H; Kurdaş, OO; Yaşar, B, 2010
)
2.11
"Erdosteine is a new thiol compound with effects on bacterial adhesiveness as well as antioxidant and mucoactive properties. "( The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Bottrighi, P; Da Porto, R; Dallari, R; De Gugliemo, M; Dolcetti, A; Garuti, G; Grandi, P; Guffanti, E; Moretti, M; Potena, A; Roversi, P, 2004
)
2.04
"Erdosteine is a potent antioxidant and mucolytic agent."( The effects of isoniazid on hippocampal NMDA receptors: protective role of erdosteine.
Cicek, E; Delibas, N; Gokalp, O; Ozcelik, N; Ozer, MK; Sutcu, R; Uz, E; Yilmaz, HR, 2005
)
1.28
"Erdosteine is a mucolytic drug whose metabolization gives rise to an active metabolite with an SH group (Met I), which reduces neutrophil release of reactive oxygen species and the peroxynitrite generated by the reaction of superoxide anion with nitric oxide, thus disrupting the phlogogenic loop sustained by activated neutrophils. "( Effect of metabolite I of erdosteine on the release of human neutrophil elastase.
Braga, PC; Culici, M; Dal Sasso, M; Lo Verso, R; Marabini, L; Verducci, P, 2006
)
2.08
"Erdosteine is a mucolytic agent having antioxidant properties through its active metabolites in acute injuries induced by pharmacological drugs. "( Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: a comparison of 99mTc-DMSA uptake with biochemical studies.
Cabuk, M; Demircan, N; Gurel, A; Sen, F, 2008
)
2.09
"Erdosteine is a multifactorial drug currently used in COPD for its rheologic activity on bronchial secretions and its positive effects on bacterial adhesiveness. "( Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro, RW, 2008
)
3.23
"Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. "( Erdosteine.
Dechant, KL; Noble, S, 1996
)
3.18
"Erdosteine is a new homocysteine-derived expectorant and has been reported to have many mucolytic effects. "( Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Hosoe, H; Kaise, T; Ohmori, K, 1998
)
3.19
"Erdosteine is an original drug which has been suggested as secretolytic compound and promoter of respiratory ventilation in the treatment of acute and chronic respiratory diseases. "( A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Fazzio, S; Lizzio, A; Mancini, C; Negri, P; Termini, C; Titti, G, 2000
)
1.95
"Erdosteine is a thiol derivative endowed with mucolytic, mucomodulator and free radical scavenging properties. "( Lack of gastric adverse effects of erdosteine in rats and men.
Amato, A; Civello, IM; De Giovanni, L; Fregnan, GB; Murari, G; Rabitti, C; Sovera, A, 1991
)
2
"Erdosteine is a new thioderivative endowed with mucokinetic, mucolytic, and free-radical-scavenging properties. "( Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Casadei, MC; Fregnan, GB; Guerzoni, P; Marchioni, CF; Moretti, M; Muratori, M; Scuri, R, 1990
)
2.11

Effects

Erdosteine has been shown to protect numerous tissues, particularly those in the liver. It has dual effects on hemostasis via its different metabolites, which occur in different doses.

ExcerptReferenceRelevance
"Erdosteine has an effect of protection against lead-induced oxidative stress which is not worse than that of EDTA."( The influence of erdosteine administration on lead-induced oxidative stress in rat muscle.
Dobrakowski, M; Kasperczyk, A; Kasperczyk, S; Machoń-Grecka, A; Maciejczyk, M; Nowak, P; Pryzwan, T; Szczęsny, P, 2022
)
1.78
"Erdosteine has been shown to protect numerous tissues, particularly those in the liver."( Erdosteine reduces cytotoxicity induced by alpha- and beta-amanitin, but not gamma-amanitin, in CA3 hepatocyte cultures.
Bayram, R; Kaya, E; Yaykasli, KO; Yilmaz, I, 2022
)
2.89
"Erdosteine has an effect of protection against lead-induced oxidative stress which is not worse than that of EDTA."( The influence of erdosteine administration on lead-induced oxidative stress in rat muscle.
Dobrakowski, M; Kasperczyk, A; Kasperczyk, S; Machoń-Grecka, A; Maciejczyk, M; Nowak, P; Pryzwan, T; Szczęsny, P, 2022
)
1.78
"Erdosteine has recently shown important anti-oxidant properties, including the ability to reduce 8-isoprostane in COPD patients."( Erdosteine affects eicosanoid production in COPD.
Dal Negro, RW; Micheletto, C; Tognella, S; Visconti, M, 2011
)
2.53
"Erdosteine has dual effects on hemostasis via its different metabolites, which occur in different doses."( Dual effects of erdosteine on hemostasis via its different metabolites in young rats.
Arica, S; Arica, V; Basarslan, F; Erden, ES; Kaya, H; Oktar, S; Ozturk, OH; Tutanc, M, 2011
)
1.44
"Erdosteine has positive effects on mucus rheology and transport due to the active metabolite (Metabolite I) which contains a free thiol group. "( Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Assereto, R; Balli, F; Bergamini, B; Calistru, P; Ciofu, EP; Domenici, R; Doros, G; Dragomir, D; Gherghina, I; Iordachescu, F; Murgoci, G; Orasanu, D; Plesca, D; Vaccaro, A, 2007
)
2.11

Treatment

Erdosteine was treated orally for 15 days at a dose of 10 mg/kg/day. Treatment increased the activities of antioxidant enzymes and decreased macrophage and neutrophil accumulation, thereby ameliorating the inflammatory effects of OA treatment.

ExcerptReferenceRelevance
"Erdosteine pretreatment increased the activities of the antioxidant enzymes, catalase, and glutathione peroxidase (0.16 ± 0.03 k/g and 0.3 ± 0.01 U/mg protein, respectively, for OA versus 0.33 ± 0.05 k/g and 0.34 ± 0.01 U/mg protein, respectively, for OA + erdosteine; P < 0.05 for both)."( Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
Erdem, A; Fadillioglu, E; Gedikli, E; Karaismailoglu, S; Muftuoglu, S; Tuncer, M; Yersal, N, 2017
)
1.5
"Erdosteine pretreatment increased the activities of antioxidant enzymes and decreased macrophage and neutrophil accumulation, thereby ameliorating the inflammatory effects of OA treatment. "( Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
Erdem, A; Fadillioglu, E; Gedikli, E; Karaismailoglu, S; Muftuoglu, S; Tuncer, M; Yersal, N, 2017
)
2.23
"Erdosteine was treated orally for 15 days at a dose of 10 mg/kg/day."( Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats.
Ciçek, E; Gökalp, O; Ozçelik, N; Ozer, MK; Uz, E; Yilmaz, HR, 2008
)
1.32
"Erdosteine treatment also increased the activities of catalase (CAT) and glutathione peroxidase (GSH-Px) in comparison with the DXR group."( Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
Erdoğan, H; Fadillioğlu, E; Kuku, I; Söğüt, S,
)
1.17
"Erdosteine treatment was associated with improved neurological function in the postoperative period. "( Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord.
Akyol, O; Ege, E; Gurel, A; Ilhan, A; Ozen, S, 2004
)
3.21
"Erdosteine treatment with rotenone led to an increase in catalase (CAT) and superoxide dismutase (SOD) activities in comparison with the rotenone group (P < 0.05)."( Protective effects of erdosteine on rotenone-induced oxidant injury in liver tissue.
Fadillioglu, E; Idiz, N; Ilhan, A; Iraz, M; Sahin, S; Terzi, A, 2004
)
1.36
"Erdosteine treatment ameliorated lipid peroxidation after torsion/detorsion in ipsilateral testis (p < 0.05)."( The protective role of erdosteine on testicular tissue after testicular torsion and detorsion.
Akaydin, Y; Duru, M; Gergerlioglu, HS; Koc, A; Narci, A; Sogut, S, 2005
)
1.36
"Erdosteine and NAC treatment did not cause any significant change in the activity of superoxide dismutase (SOD) in comparison with the IR group, even if the SOD activity increased in IR groups than in the control group."( Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury: protective effects of erdosteine and N-acetylcysteine.
Erdogan, H; Fadillioglu, E; Irmak, MK; Uçar, M; Yagmurca, M, 2006
)
1.27
"Erdosteine treated APAP groups showed milder tubular degeneration, epithelial vacuolization in the proximal tubules, lesser cellular desquamation and better morphology when compared with APAP groups."( Erdosteine against acetaminophen induced renal toxicity.
Akcay, A; Bayrak, R; Isik, B; Sogut, S, 2006
)
2.5
"The erdosteine treatment induced a significant improvement of MCT while placebo was inactive (mean % variation +/- SE against their baseline values being +60.4 +/- 18.4 and -3.0 +/- 5.9, respectively)."( Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Casalini, A; D'Ippolito, R; Del Donno, M; Fregnan, GB; Olivieri, D, 1991
)
1.14
"Treatment with erdosteine ameliorated the histopathological abnormalities when compared with the control group. "( Erdosteine ameliorates the harmful effects of ischemia-reperfusion injury on the liver of rats.
Adiyaman, Z; Barlas, AM; Cavusoglu, T; Celepli, P; Erel, S; Hucumenoglu, S; Kismet, K; Kuru, S; Pekcici, R; Senes, M, 2017
)
2.25
"Treatment with erdosteine and/or ALA was found to preserve the loss of reproductive capacity normally observed after ovarian torsion."( Antioxidant effect of erdosteine and lipoic acid in ovarian ischemia-reperfusion injury.
Dokuyucu, R; Duru, M; Gokce, H; Karateke, A; Karateke, F; Kurt, RK; Ozcan, O; Ozturk, S; Tas, ZA, 2014
)
1.06
"Pretreatment with erdosteine protects HEI-OC1 cells from cisplatin-medicated apoptosis, which is characterized by increase in nuclear fragmentation, DNA laddering, sub-G0/G1 phase, H2AX phosphorylation, PARP cleavage, and caspase-3 activity."( Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.
Choe, SK; Hong, GY; Kim, SJ; Lee, JN; Lim, DJ; Lim, H; Moon, SK; Park, C; Park, R, 2015
)
2.18
"The treatment with erdosteine was well tolerated."( The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola, M; Floriani, I; Page, CP, 2010
)
0.97
"Treatment with erdosteine is associated with a significant benefit in terms of symptom amelioration both vs placebo and mucolytics in patients with CB/COPD. "( The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola, M; Floriani, I; Page, CP, 2010
)
1.01
"Co-treatment with erdosteine (10 mg kg(-1)day(-1)) attenuated the increase in the plasma creatinine and BUN levels, and significantly prevented the increase in tissue and plasma AD and XO activities (P<0.05)."( In vivo evidence suggesting a role for purine-catabolizing enzymes in the pathogenesis of cisplatin-induced nephrotoxicity in rats and effect of erdosteine against this toxicity.
Kotuk, M; Ozyurt, H; Söğüt, S; Ulu, R; Yildirim, Z; Yilmaz, HR,
)
0.66
"Pretreatment with erdosteine significantly diminished tissue MDA level, MPO and XO activities."( Erdosteine improves oxidative damage in a rat model of renal ischemia-reperfusion injury.
Armutcu, F; Cihan, A; Gurel, A; Numanoglu, KV; Unalacak, M,
)
1.9
"Treatment with erdosteine, NAC, and vitamin E significantly reduced the rate of nicotine-induced pulmonary epithelial cell apoptosis, and there were no significant differences in apoptosis among the three antioxidants groups."( The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
Demiralay, R; Erdem, H; Gürsan, N, 2006
)
1.03
"Pretreatment with erdosteine and pretreatment with N-acetylcysteine at a dose of 10 mg kg(-1) had no protective effect on LPS-induced lung injury."( Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury.
Demiralay, R; Demirci, E; Erdogan, G; Gürsan, N; Ozbilim, G,
)
0.75
"Posttreatment with erdosteine and NAC significantly reduced the rate of LPS-induced epithelial cell apoptosis."( Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine.
Demiralay, R; Erdem, H; Gürsan, N, 2006
)
0.88

Toxicity

Erdosteine acts in the kidney as a potent scavenger of free radicals to prevent or ameliorate the toxic effects of gamma irradiation. It might provide substantial protection against radiation-induced inflammatory damage.

ExcerptReferenceRelevance
" Safety was evaluated with adverse drug reactions reporting, arterial blood pressure, heart rate and laboratory tests monitoring."( Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Hanard, T; Mancini, C; Marchioni, CF; Noseda, G; Polu, JM; Taytard, A, 1995
)
0.56
" The potent free radical scavenger erdosteine may have protective potential in this process and it will become a promising drug in the prevention of this undesired side-effect of cisplatin, but further studies are needed to illuminate the exact protection mechanism of erdosteine against cisplatin-induced nephrotoxicity."( In vivo evidence suggesting a role for purine-catabolizing enzymes in the pathogenesis of cisplatin-induced nephrotoxicity in rats and effect of erdosteine against this toxicity.
Kotuk, M; Ozyurt, H; Söğüt, S; Ulu, R; Yildirim, Z; Yilmaz, HR,
)
0.61
" The use of antioxidants reduces the adverse effects of CsA."( The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats.
Akcay, A; Bayrak, R; Karanfil, A; Kaya, A; Ozkara, A; Sahin, S; Selcoki, Y; Uz, B; Uz, E, 2007
)
0.64
" Erdosteine prevented APAP-induced liver injury and toxic side effects probably through the antioxidant and radical scavenging effects of erdosteine."( Effects of erdosteine on acetaminophen-induced hepatotoxicity in rats.
Duru, M; Helvaci, R; Kaya, H; Koc, A; Kozlu, T; Kuvandik, G; Nacar, A; Sogüt, S; Yonden, Z, 2008
)
1.65
" The use of antioxidants reduces the adverse effects of CsA."( Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats.
Bayrak, R; Delibasi, T; Ekiz, F; Erarslan, E; Koca, C; Turkcu, UO; Uz, B, 2011
)
0.76
"No patient experienced any adverse effect during the study."( Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis - a pilot study.
Hoza, J; Kellnerova, R; Salzman, R; Schalek, P; Starek, I, 2013
)
0.7
" Erdosteine acts in the kidney as a potent scavenger of free radicals to prevent or ameliorate the toxic effects of gamma irradiation as shown in the biochemical and histopathological changes and might provide substantial protection against radiation-induced inflammatory damage."( Protective effects of erdosteine against nephrotoxicity caused by gamma radiation in male albino rats.
Elkady, AA; Ibrahim, IM, 2016
)
1.66
"Cisplatin has many adverse effects, which are a major limitation to its use, including ototoxicity, neurotoxicity, and nephrotoxicity."( Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.
Choe, SK; Hong, GY; Kim, SJ; Lee, JN; Lim, DJ; Lim, H; Moon, SK; Park, C; Park, R, 2015
)
1.86
" The frequency of adverse events (AEs) was also investigated."( Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Calzetta, L; Cazzola, M; Matera, MG; Page, C; Puxeddu, E; Rogliani, P, 2019
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Further confirmation that there was no interference between erdosteine and theophylline was obtained from the data available on the group of patients receiving only theophylline, since its plasma levels and related pharmacokinetic parameters were identical to those obtained in patients receiving both drugs."( Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Casadei, MC; Fregnan, GB; Guerzoni, P; Marchioni, CF; Moretti, M; Muratori, M; Scuri, R, 1990
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The lower dosage of the 5-10 years range in comparison with the 2-4 years range was established on the base of bioavailability characteristics of the two pharmaceutical forms."( A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Fazzio, S; Lizzio, A; Mancini, C; Negri, P; Termini, C; Titti, G, 2000
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. The cis platin dosage was 14 mg/kg and for erdsteine, 500  mg/kg. Four simple, sensitive, economical, and eco-friendly spectrophotometric and spectrofluorimetric methods were used.

ExcerptRelevanceReference
" The lower dosage of the 5-10 years range in comparison with the 2-4 years range was established on the base of bioavailability characteristics of the two pharmaceutical forms."( A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Fazzio, S; Lizzio, A; Mancini, C; Negri, P; Termini, C; Titti, G, 2000
)
0.51
" dosage of 20 mg kg(-1) body wt."( Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
Erdoğan, H; Fadillioğlu, E; Kuku, I; Söğüt, S,
)
0.45
"The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity."( Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner.
Gergerlioglu, S; Iraz, M; Kotuk, M; Ozyurt, H; Söğüt, S; Yağmurca, M; Yildirim, Z; Yilmaz, HR,
)
0.62
" VCM was administered intraperitoneally in the dosage of 200 mg/kg twice daily for 7 days."( Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver.
Arslan, C; Cam, H; Olgar, S; Sahin, M; Tunc, SE; Uz, E; Yilmaz, HR, 2006
)
0.66
" LPS was intraperitoneally injected at a dosage of 20mg/kg."( Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine.
Demiralay, R; Erdem, H; Gürsan, N, 2006
)
0.56
" Absorption correction method and Dual wavelength method were developed for the estimation of Cefixime (CEF) and Erdosteine (ERDO) in capsule dosage form."( Simultaneous estimation of Cefixime and Erdosteine in capsule dosage form by spectrophotometric method.
Dhoka, MV; Gandhi, SV; Gawande, VT; Joshi, PP; Patil, NG, 2009
)
0.83
"788) h, which provided a pharmacokinetic basis for the rational dosage regimen."( [Simultaneous determination of erdosteine and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry with pre-column derivatization].
Chen, XY; Jin, J; Ma, ZY; Zhang, YF; Zhong, DF, 2013
)
0.68
" These methods were successfully applied to the determination of erdosteine in bulk powder, laboratory-prepared mixtures containing different percentages of the degradation products, and pharmaceutical dosage forms."( Stability-indicating methods for the determination of erdosteine in the presence of its acid degradation products.
Badawey, AM; El-Aleem, Ael-A; Lamie, NT; Moustafa, NM,
)
0.62
" The cisplatin dosage was 14 mg/kg and for erdosteine, 500 mg/kg."( The impact of erdosteine on cisplatin-induced ototoxicity: a proteomics approach.
Akinpelu, OV; Daniel, SJ; Garnier, D; Salehi, P; Waissbluth, S, 2017
)
1.08
"Four simple, sensitive, economical, and eco-friendly spectrophotometric and spectrofluorimetric methods for the assay of erdosteine (ERD) in bulk and dosage form have been developed and validated as per the current ICH guidelines."( Multiple green spectroscopic methods for erdosteine determination in bulk and dosage form with extensive greenness evaluation.
Belal, TS; El-Kimary, EI; El-Yazbi, AF; Khalil, HA, 2023
)
1.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency94.39180.000714.592883.7951AID1259369
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency2.68320.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (3.70)18.7374
1990's13 (8.02)18.2507
2000's64 (39.51)29.6817
2010's59 (36.42)24.3611
2020's20 (12.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.61 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index128.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (15.70%)5.53%
Reviews12 (6.98%)6.00%
Case Studies2 (1.16%)4.05%
Observational0 (0.00%)0.25%
Other131 (76.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) [NCT01176318]Phase 40 participants (Actual)Interventional2010-08-10Withdrawn(stopped due to grant was withdrawn no financial support to conduct the study.)
The Efficacy and Safety of Erdosteine in the Long-term Therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study [NCT01032304]Phase 3492 participants (Anticipated)Interventional2009-08-31Active, not recruiting
A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose_Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated With Chronic Obstructive Pulmonary Disease [NCT00338507]Phase 2400 participants Interventional2006-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]